An observational study in Hypertension and Type 2 Diabetes, sponsored by AstraZeneca. Completed at 19 sites in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-09.
Sponsored by AstraZeneca · Observational
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP\<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=\<7%. To observe the proportion of patients achieving fasting plasma glucose\<110 mg%. To identify factors for not achieving BP\<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 1,060 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
type 2 diabetic patients who are currently using antihypertensive treatment for at least 3 months, with same regimen for a minimum of 4 weeks prior to the survey
Exclusion Criteria:
The number of patients achieving the BP<130/80 mmHg
The percentage of patients achieving the BP<130/80 mmHg
The number and percentage of patients achieving the BP<130/80 mmHg by treatment groups
The number and percentage of patients achieving HbA1c=<7%
The number and percentage of patients achieving the FPG<110 mg%
The association between unachievement of BP<130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...)
The number and percentage of patients with positive proteinuria by treatment groups
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca